Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Publication Date
2-1-2024
PubMed ID:
Citation
Carneiro, B. A., Cavalcante, L., Mahalingam, D., Saeed, A., Safran, H., Ma, W. W., Coveler, A. L., Powell, S., Bastos, B., Davis, E., Sahai, V., Mikrut, W., Longstreth, J., Smith, S., Weisskittel, T., Li, H., Borden, B. A., Harvey, R. D., Sahebjam, S., Cervantes, A., … Munster, P. (2024). Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(3), 522–531. https://doi.org/10.1158/1078-0432.CCR-23-1916